The top 10 biopharma stock gainers and losers for the week.

As COVID-19 vaccinations continue to roll out, momentum builds with strong phase III data for what could become the fourth and fifth walls of defense in the U.S.

With the massive amounts of capital raised by global public and private biopharmaceutical companies last year generating approximately $134 billion – a total that was almost double the previous record of about $69 billion raised in 2015 – it is not surprising that financing for the regenerative medicine and advanced therapy sector also set an annual record.

A quick look back at top stories.

The top 10 biopharma stock gainers and losers for the week.

Biopharma deal values in 2021 are already tracking about 12% ahead of this time last year, while M&A values have declined by 57%.